نتایج جستجو برای: gem

تعداد نتایج: 3625  

2017
Rongrong Zhang Yun Ru Yiping Gao Jinyin Li Shilong Mao

PURPOSE Cisplatin plus gemcitabine (GEM) is a standard regimen for the first-line treatment of advanced non-small cell lung cancer. The aim of this study was to prepare biocompatible and biodegradable polymeric prodrugs and construct nanoparticles (NPs) with layer-by-layer (LbL) technique. METHODS Platinum (Pt) (IV) complex with a carboxyl group was conjugated to the amino group of chitosan (...

Journal: :Carcinogenesis 2014
Guillaume Andrieu Muriel Quaranta Corinne Leprince Olivier Cuvillier Anastassia Hatzoglou

Gem is a small guanosine triphosphate (GTP)-binding protein within the Ras superfamily, involved in the regulation of voltage-gated calcium channel activity and cytoskeleton reorganization. Gem overexpression leads to stress fiber disruption, actin and cell shape remodeling and neurite elongation in interphase cells. In this study, we show that Gem plays a crucial role in the regulation of cort...

Journal: :European journal of cancer 2011
Feng Yang Chen Jin Dong Yang Yongjian Jiang Ji Li Yang Di Jianhua Hu Changchun Wang Quanxing Ni Deliang Fu

Strategies using carbon-based nanomaterials as carriers for delivering chemotherapeutic drugs to cancers have been described well. Here a novel magnetic lymphatic-targeting drug-delivery system, based on functionalised carbon nanotubes (fCNTs), is presented with the aim of improving the outcome of cancer with lymph node involvement. The potential therapeutic effect of gemcitabine (GEM) loading ...

Journal: :Chemical communications 2011
Saikat Khamarui Deblina Sarkar Palash Pandit Dilip K Maiti

A general strategy for fast decarboxylative difunctionalization to gem-dihalohydrin, gem-dihaloether, gem-dibromoester and cyclized bromo-1,4-dioxane synthons with outstanding regio- and stereoselectivity is demonstrated.

Journal: :Molecular biology of the cell 2007
Anastassia Hatzoglou Isabelle Ader Anne Splingard James Flanders Evelyne Saade Ingrid Leroy Sabine Traver Sandra Aresta Jean de Gunzburg

Gem is a protein of the Ras superfamily that plays a role in regulating voltage-gated Ca2+ channels and cytoskeletal reorganization. We now report that GTP-bound Gem interacts with the membrane-cytoskeleton linker protein Ezrin in its active state, and that Gem binds to active Ezrin in cells. The coexpression of Gem and Ezrin induces cell elongation accompanied by the disappearance of actin str...

2014
S. Kennedy L. Ryan A. Fraser M. E. Clegg

The Deltatrac™ II Metabolic Monitor (Datex-Ohmeda Inc.) is considered the standard reference machine in indirect calorimetry; however, it is no longer commercially available thus there is a need for new machines. The gas exchange measurement (GEM; GEM Nutrition Ltd) and the ECAL (Health Professional Solutions) are alternative measuring systems. The aim of this study was to compare the ECAL and ...

Journal: :Annals of oncology : official journal of the European Society for Medical Oncology 2015
B H O'Neil A J Scott W W Ma S J Cohen L Leichman D L Aisner A R Menter M A Tejani J K Cho J Granfortuna L Coveler O O Olowokure J C Baranda M Cusnir P Phillip J Boles R Nazemzadeh M Rarick D J Cohen J Radford L Fehrenbacher R Bajaj V Bathini P Fanta J Berlin A J McRee R Maguire F Wilhelm M Maniar A Jimeno C L Gomes W A Messersmith

BACKGROUND Rigosertib (ON 01910.Na), a first-in-class Ras mimetic and small-molecule inhibitor of multiple signaling pathways including polo-like kinase 1 (PLK1) and phosphoinositide 3-kinase (PI3K), has shown efficacy in preclinical pancreatic cancer models. In this study, rigosertib was assessed in combination with gemcitabine in patients with treatment-naïve metastatic pancreatic adenocarcin...

2016
Mustapha Tehfe Scot Dowden Hagen Kennecke Robert El-Maraghi Bernard Lesperance Felix Couture Richard Letourneau Helen Liu Alfredo Romano

INTRODUCTION The phase III MPACT trial in patients with metastatic pancreatic cancer (MPC) demonstrated superior efficacy of nab-paclitaxel (nab-P) plus gemcitabine (Gem) compared with Gem monotherapy, including the primary endpoint of overall survival (OS; median 8.7 vs. 6.6 months; hazard ratio [HR] 0.72; P < 0.001). A significant treatment difference favoring nab-P + Gem over Gem was observe...

Journal: :The Journal of pharmacology and experimental therapeutics 2004
Yoshihisa Shitara Masaru Hirano Hitoshi Sato Yuichi Sugiyama

A serious pharmacokinetic interaction between cerivastatin (CER) and gemfibrozil (GEM) has been reported. In the present study, we examined the inhibitory effects of GEM and its metabolites, M3 and gemfibrozil 1-O-beta-glucuronide (GEM-1-O-glu), on the uptake of CER by human organic anion transporting polypeptide 2 (OATP2)-expressing cells and its metabolism in cytochrome P450 expression system...

Journal: :Journal of B.U.ON. : official journal of the Balkan Union of Oncology 2013
Ping-Ying Chang Ming-Shen Dai Ching-Liang Ho Nai-Shun Yao

PURPOSE There is no optimal dosing schedule of gemcitabine (GEM) and cisplatin (CDDP) combination for cancer patients with renal failure (RF) on hemodialysis (HD). The purpose of this study was to share our experience of using GEM and CDDP in such patients. METHODS The starting dose of GEM was defined based on single-agent treatment of two cancer patients with RF. Between November 2006 and Ju...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید